Investment
Features
FeesSafety
Academy
More
Pluang+

Compare C3.ai Inc (AI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

C3.ai Inc vs Neurocrine Biosciences Inc — how do they compare? C3.ai Inc trades at $10.6 (market cap $1.59B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 10.5× C3.ai Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.

AINBIX
Market Cap
$1.59B$16.76B
Sector
TechnologyHealth
52-Week High
$19.66$185.50
52-Week Low
$7.76$123.10
Enterprise Value
$1.02B$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

C3.ai Inc

C3.ai (AI) trades at $10.22, up 3.65% with a bullish technical signal. The company shows revenue growth to $389M in 2025 but continues significant losses with a -187.95% net income margin. Recent recognition as a leader in AI platforms by Forrester Research (August 10, 2026) provides positive momentum, though cash flow remains negative. Analyst consensus is mixed with 21% buy ratings and a $10.20 price target slightly below current levels.

The outlook remains challenging with persistent losses offset by strong market positioning in enterprise AI. Investment opportunity lies in the company's leadership recognition and sector growth potential, while risks include unsustainable cash burn and competitive pressures. The stock faces near-term resistance at $11 with support at $10.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About C3.ai Inc

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type

Read more on AI

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX